Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 16.70% is 120% above its 5-year average of -82.23%, near the high end of its 5-year range (-315.32%–28.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 131.08% above its 12-month average of -53.75%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 16.70%.
RETURN ON EQUITY (ROE)
16.70%
RETURN ON EQUITY (ROE) AVG TTM
-53.75%
RETURN ON EQUITY (ROE) AVG 3Y
-44.03%
RETURN ON EQUITY (ROE) AVG 5Y
-82.23%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+131.08%
CURRENT VS 3Y AVG
+137.93%
CURRENT VS 5Y AVG
+120.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+139.76%
vs the sector median at left
Spero Therapeutics, Inc.
Market Cap
$68.90M
Return on Equity (ROE)
16.70%
TTM Avg
-53.75%
3Y Avg
-44.03%
5Y Avg
-82.23%
Market Cap
$69.61M
Return on Equity (ROE)
-29.15%
TTM Avg
47.40%
3Y Avg
90.52%
5Y Avg
62.16%
Market Cap
$68.10M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$67.52M
Return on Equity (ROE)
-38.55%
TTM Avg
-81.03%
3Y Avg
-175.38%
5Y Avg
-133.71%
Market Cap
$70.63M
Return on Equity (ROE)
-35444.23%
TTM Avg
-17872.82%
3Y Avg
-9061.56%
5Y Avg
-6066.76%
Market Cap
$71.23M
Return on Equity (ROE)
-178.06%
TTM Avg
-193.35%
3Y Avg
-164.22%
5Y Avg
-125.75%
Market Cap
$65.87M
Return on Equity (ROE)
N/A
TTM Avg
-26.44%
3Y Avg
-559.66%
5Y Avg
-417.87%
Market Cap
$65.86M
Return on Equity (ROE)
-122.71%
TTM Avg
-558.46%
3Y Avg
-307.41%
5Y Avg
-314.14%
Market Cap
$65.85M
Return on Equity (ROE)
-35.13%
TTM Avg
-26.80%
3Y Avg
-19.63%
5Y Avg
-14.70%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.90M | 16.70% | -53.75% | -44.03% | -82.23% |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | -29.15% | 47.40% | 90.52% | 62.16% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 68.12% | -94.32% | -166.28% | -128.51% |
| iBio, Inc. (IBIO)vs › | $67.52M | -38.55% | -81.03% | -175.38% | -133.71% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | -35444.23% | -17872.82% | -9061.56% | -6066.76% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | -178.06% | -193.35% | -164.22% | -125.75% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | N/A | -26.44% | -559.66% | -417.87% |
| Cingulate Inc. (CING)vs › | $65.86M | -122.71% | -558.46% | -307.41% | -314.14% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -35.13% | -26.80% | -19.63% | -14.70% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -724.01% | 352.19% | 76.05% | 9.78% |
ROE
16.7%
ROA
14.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 16.70% |
| 2026-03-31 | 28.78% |
| 2025-12-31 | 14.52% |
| 2025-09-30 | -165.46% |
| 2025-06-30 | -163.28% |
| 2025-03-31 | -206.31% |
| 2024-12-31 | -148.66% |
| 2024-09-30 | 5.36% |
| 2024-06-30 | 21.68% |
| 2024-03-31 | 24.32% |
| 2023-12-31 | 21.34% |
| 2023-09-30 | -3.01% |
| 2023-06-30 | -18.41% |
| 2023-03-31 | -41.41% |
| 2022-12-31 | -61.13% |
| 2022-09-30 | -315.31% |
| 2022-06-30 | -315.32% |
| 2022-03-31 | -165.13% |
| 2021-12-31 | -101.66% |
| 2021-09-30 | -70.69% |
| 2021-06-30 | -83.67% |
| 2021-03-31 | -62.64% |
| 2020-12-31 | -59.29% |
| 2020-09-30 | -63.77% |
| 2020-06-30 | -113.22% |
| 2020-03-31 | -95.98% |
| 2019-12-31 | -81.70% |
| 2019-09-30 | -50.21% |
| 2019-06-30 | -35.94% |
| 2019-03-31 | -31.95% |
| 2018-12-31 | -35.96% |
| 2018-09-30 | -36.61% |
| 2018-06-30 | -69.21% |
| 2018-03-31 | -59.59% |
| 2017-12-31 | -46.67% |
| 2017-09-30 | -134.19% |
| 2017-06-30 | -89.90% |
